Chemotherapy-associated changes of histopathological features of mycobacterium ulcerans lesions in a buruli ulcer mouse model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 687-696

  Ruf, Marie Thérèse ^a,b   Schütte, Daniela ^c   Chauffour, Aurélie ^c   Jarlier, Vincent ^c   Ji, Baohong ^c   Pluschke, Gerd ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BACTERIAL GROWTH; BACTERIUM ISOLATION; BAGG ALBINO MOUSE; BURULI ULCER; CELL INFILTRATION; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; FEMALE; FOOT PAD; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INOCULATION; LEG SWELLING; MACROPHAGE; MOUSE; MYCOBACTERIUM ULCERANS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BURULI ULCER; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; FOOT; HUMANS; MICE; MICE, INBRED BALB C; MYCOBACTERIUM ULCERANS; RIFAMPIN; STREPTOMYCIN; TREATMENT OUTCOME;

EID: 84856072893     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05543-11     Document Type: Article

References (45)

1. Adusumilli S, et al. 2005. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell. Microbiol. 7:1295-1304. (Pubitemid 41179422)
2. Amofah G, et al. 2002. Buruli ulcer in Ghana: results of a national case search. Emerg. Infect. Dis. 8:167-170. (Pubitemid 34202439)
3. Chauty A, et al. 2007. Promising clinical efficacy of streptomycinrifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob. Agents Chemother. 51:4029-4035. (Pubitemid 350057802)
4. Chauty A, et al. 2011. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin. Infect. Dis. 52:94-96.
5. Coutanceau E, et al. 2005. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell. Microbiol. 7:1187-1196. (Pubitemid 41030943)
6. Debacker M, et al. 2004. Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg. Infect. Dis. 10:1391-1398. (Pubitemid 39014151)
7. Dega H, et al. 2000. Mycobacterium ulcerans infection. Ann. Med. Interne (Paris) 151:339-344. (In French.)
8. Diaz D, et al. 2006. Use of the immunodominant 18-kilodalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin. Vaccine Immunol. 13:1314-1321. (Pubitemid 46086896)
9. Durnez L, et al. 2010. Terrestrial small mammals as reservoirs of Mycobacterium ulcerans in Benin. Appl. Environ. Microbiol. 76:4574-4577.
10. Eddyani M, et al. 2004. Potential role for fish in transmission of Mycobacterium ulcerans disease (Buruli ulcer): an environmental study. Appl. Environ. Microbiol. 70:5679-5681. (Pubitemid 39279647)
11. Fyfe JAM, et al. 2010. A major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl. Trop. Dis. 4:e791.
12. Guarner J, et al. 2003. Histopathologic features of Mycobacterium ulcerans infection. Emerg. Infect. Dis. 9:651-656. (Pubitemid 36676359)
13. Hayman J. 1993. Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J. Clin. Pathol. 46:5-9. (Pubitemid 23039578)
14. Hayman J, McQueen A. 1985. The pathology of Mycobacterium ulcerans infection. Pathology 17:594-600. (Pubitemid 16206726)
15. Ji B, et al. 2009. Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 53:2955-2959.
16. Ji B, Chauffour A, Robert J, Jarlier V. 2008. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 52:1912-1916. (Pubitemid 351758522)
17. Ji B, Chauffour A, Robert J, Lefrançois S, Jarlier V. 2007. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 51:3737-3739. (Pubitemid 47519368)
18. Ji B, et al. 2006. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob. Agents Chemother. 50:1921-1926. (Pubitemid 43807506)
19. Johnson PDR, et al. 2005. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med. 2:e108.
20. Kibadi K, et al. 2010. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl. Trop. Dis. 4:e736.
21. Kim SH, Kook MC, Shin YK, Park SH, Song HG. 2004. Evaluation of antigen retrieval buffer systems. J. Mol. Hist. 35:409-416. (Pubitemid 40576027)
22. Kumar V. 2004. High resolution shadowing of Mycobacterium leprae. Biotech. Histochem. 79:197-201. (Pubitemid 40109610)
23. Lefrançois S, Robert J, Chauffour A, Ji B, Jarlier V. 2007. Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin. Antimicrob. Agents Chemother. 51:645-650. (Pubitemid 46185285)
24. Marsollier L, et al. 2002. Aquatic insects as a vector for Mycobacterium ulcerans. Appl. Environ. Microbiol. 68:4623-4628. (Pubitemid 34988148)
25. Marsollier L, et al. 2004. Aquatic snails, passive hosts of Mycobacterium ulcerans. Appl. Environ. Microbiol. 70:6296-6298. (Pubitemid 39471881)
26. Marsollier L, et al. 2004. Aquatic plants stimulate the growth of and biofilm formation by Mycobacterium ulcerans in axenic culture and harbor these bacteria in the environment. Appl. Environ. Microbiol. 70:1097-1103. (Pubitemid 38568236)
27. Merritt RW, et al. 2010. Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl. Trop. Dis. 4:e911.
28. Nienhuis WA, et al. 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375:664-672.
29. Portaels F, et al. 2001. Mycobacterium ulcerans in wild animals. Rev. Sci. Tech. 20:252-264. (Pubitemid 33585267)
30. Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne PA, Meyers WM. 1999. Insects in the transmission of Mycobacterium ulcerans infection. Lancet 353:986. (Pubitemid 29132618)
31. Portaels F, et al. 2004. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect. Immun. 72:62-65. (Pubitemid 38018161)
32. Ruf M-T, et al. 2011. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl. Trop. Dis. 5:e1252.
33. Sarfo FS, et al. 2010. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob. Agents Chemother. 54:3678-3685.
34. Schütte D, UmBoock A, Pluschke G. 2009. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Br. J. Dermatol. 160:273-283.
35. Schütte D, et al. 2007. Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl. Trop. Dis. 1:e2.
36. Silva MT, Portaels F, Pedrosa J. 2009. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect. Dis. 9:699-710.
37. Sizaire V, Nackers F, Comte E, Portaels F. 2006. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect. Dis. 6:288-296.
38. Thangaraj HS, Evans MR, Wansbrough-Jones MH. 1999. Mycobacterium ulcerans disease; Buruli ulcer. Trans. R. Soc. Trop. Med. Hyg. 93:337-340. (Pubitemid 29405849)
39. Toll A, et al. 2005. Aggressive multifocal Buruli ulcer with associated osteomyelitis in an HIV-positive patient. Clin. Exp. Dermatol. 30:649-651. (Pubitemid 41499819)
40. Torrado E, et al. 2007. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect. Immun. 75:977-987. (Pubitemid 46203463)
41. Vandelannoote K, et al. 2010. Application of real-time PCR in Ghana, a Buruli ulcer-endemic country, confirms the presence of Mycobacterium ulcerans in the environment. FEMS Microbiol. Lett. 304:191-194.
42. van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K. 1999. Mycobacterium ulcerans infection. Lancet 354:1013-1018. (Pubitemid 29438417)
43. van der Werf TS, et al. 2005. Mycobacterium ulcerans disease. Bull. World Health Organ. 83:785-791.
44. WHO. 2001. Buruli ulcer. Diagnosis of Mycobacterium ulcerans disease. WHO/CDS/CPE/GBUI/2001.4. World Health Organization, Geneva, Switzerland.
45. World Health Organization. 2004. Provisional guidance on the role of specific antibiotics in the managment of Mycobacterium ulcerans disease. World Health Organization, Geneva, Switzerland.